Forskning ved Københavns Universitet - Københavns Universitet


Biologisk behandling af spondylitis ankylopoietica

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • S. Freiesleben
  • M. Schou
All of the three well-known TNF alpha inhibitors (infliximab, adalimumab and etanercept) have a rapidly occurring and long-lasting effect in ankylosing spondylitis (AS). The IL-1 antagonist, anakinra, has been investigated in two open label studies with partially conflicting results. Apart from infusion reactions and local reactions which rarely are of clinical importance, infections appear significantly more often in the TNF alpha inhibitor groups compared to placebo groups. Most of the infections observed have been minor, but serious infections, including tuberculosis, have been described
Udgivelsesdato: 2008/6/9
TidsskriftUgeskrift for læger
Udgave nummer24
Sider (fra-til)2140-2145
Antal sider5
StatusUdgivet - 2008

ID: 10951599